Susquehanna International Group, LLP Fibrogen Inc Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Fibrogen Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 55,362 shares of FGEN stock, worth $18,269. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,362

Previous 483,100 88.54%

Holding current value

$18,269

Previous $429,000 94.87%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $141,153 - $538,949	-427,738 Reduced 88.54%	55,362 $22,000
Q2 2024 Aug 15, 2024	BUY	$0.89 - $2.36 $429,959 - $1.14 Million	483,100 New	483,100 $429,000
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $17,966 - $43,024	47,280 Added 24.02%	244,083 $217,000
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $120,867 - $432,981	152,997 Added 349.26%	196,803 $169,000
Q2 2023 Aug 11, 2023	SELL	$2.49 - $20.59 $437,662 - $3.62 Million	-175,768 Reduced 80.05%	43,806 $118,000
Q1 2023 May 16, 2023	BUY	$15.95 - $25.18 $2.47 Million - $3.9 Million	155,051 Added 240.3%	219,574 $4.1 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $349,558 - $467,043	-26,342 Reduced 28.99%	64,523 $1.03 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $326,826 - $418,567	28,669 Added 46.09%	90,865 $1.18 Million
Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $611,951 - $998,853	-77,072 Reduced 55.34%	62,196 $657,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $3.08 Million - $4.3 Million	-256,199 Reduced 64.78%	139,268 $1.67 Million
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $337,222 - $522,644	33,960 Added 9.39%	395,467 $5.58 Million
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $177,478 - $464,441	-17,434 Reduced 4.6%	361,507 $3.7 Million
Q2 2021 Aug 11, 2021	BUY	$18.57 - $35.68 $5.05 Million - $9.7 Million	271,919 Added 254.08%	378,941 $10.1 Million
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $1.93 Million - $3.47 Million	-62,330 Reduced 36.8%	107,022 $3.72 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $1.8 Million - $2.38 Million	48,663 Added 40.32%	169,352 $6.28 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $319,146 - $358,813	-7,886 Reduced 6.13%	120,689 $4.96 Million
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $1.83 Million - $2.4 Million	-56,096 Reduced 30.38%	128,575 $5.21 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $3.87 Million - $7.63 Million	-166,027 Reduced 47.34%	184,671 $6.42 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $1.64 Million - $2.28 Million	47,484 Added 15.66%	350,698 $15 Million
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $3.09 Million - $4.05 Million	83,664 Added 38.11%	303,214 $11.2 Million
Q2 2019 Aug 16, 2019	BUY	$35.13 - $55.53 $538,683 - $851,497	15,334 Added 7.51%	219,550 $9.92 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $5.1 Million - $8.07 Million	145,317 Added 246.72%	204,216 $9.23 Million
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $18.2 Million - $25.5 Million	-425,326 Reduced 87.84%	58,899 $3.2 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $12.7 Million - $20.1 Million	334,254 Added 222.88%	484,225 $22.4 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $744,905 - $889,784	-13,231 Reduced 8.11%	149,971 $9.11 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $1.29 Million - $1.87 Million	-28,823 Reduced 15.01%	163,202 $10.2 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $5.45 Million - $7.4 Million	-120,102 Reduced 38.48%	192,025 $8.87 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $10.6 Million - $15.2 Million	252,162 Added 420.52%	312,127 $14.8 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $2 Million - $3.23 Million	59,965	59,965 $3.23 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $30.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Fibrogen Inc Transaction History